$MYNZ's Strategic Moves: FDA Breakthrough and Thermo Fisher $MYNZ has submitted an application to the FDA for Breakthrough Device Designation for its next-generation colorectal cancer screening test, aiming to accelerate approval.
Additionally, the company has partnered with Thermo Fisher Scientific to develop and potentially commercialize this innovative product, leveraging Thermo Fisher's advanced technologies.
These strategic initiatives position $MYNZ for significant growth in the cancer diagnostics market.